1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides an overview of the Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Spinocerebellar ataxias (SCAs) are a group of inherited conditions that affect the brain and spinal cord causing progressive difficulty with coordination. Symptoms include poor coordination, unsteady walk and a tendency to stumble, change in speech and difficulty swallowing.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Spinocerebellar Ataxia (SCA) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Spinocerebellar Ataxia (SCA) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 4, 13 and 8 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 4 and 2 molecules, respectively.
Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Spinocerebellar Ataxia (SCA) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Spinocerebellar Ataxia (SCA) (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Spinocerebellar Ataxia (SCA) (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Spinocerebellar Ataxia (SCA) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Spinocerebellar Ataxia (SCA) - Overview
- Spinocerebellar Ataxia (SCA) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Spinocerebellar Ataxia (SCA) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Spinocerebellar Ataxia (SCA) - Companies Involved in Therapeutics Development
- Spinocerebellar Ataxia (SCA) - Drug Profiles
- Spinocerebellar Ataxia (SCA) - Dormant Projects
- Spinocerebellar Ataxia (SCA) - Discontinued Products
- Spinocerebellar Ataxia (SCA) - Product Development Milestones
- Featured News & Press Releases
- May 23, 2022: Biohaven provides update on phase 3 clinical trial evaluating troriluzole for spinocerebellar ataxia (SCA)
- Nov 08, 2021: Seelos Therapeutics announces FDA acceptance of investigational new drug application and grant of fast track designation for SLS-005 (IV Trehalose) for the treatment of Spinocerebellar Ataxia
- Oct 07, 2021: Blade Therapeutics announces publication of preclinical evidence supporting neuroprotective effects of proprietary calpain inhibitor in a rare inherited neurodegenerative disease
- Jun 29, 2021: US FDA grants VICO therapeutics orphan-drug designation for VO659, an investigational therapy for spinocerebellar ataxia
- Apr 13, 2021: Biohaven announces presentations on troriluzole at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
- Mar 29, 2021: SM Life Sciences submits IND for spinal cerebellar ataxia treatment
- Feb 10, 2021: European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an investigational herapy for spinocerebellar ataxia
- Dec 21, 2020: Seelos Therapeutics announces issuance of a patent for Trehalose (SLS-005) in Israel
- Nov 11, 2020: Biohaven Pharmaceuticals inaugural partner Of National Ataxia Foundation's drug development collaborative
- Jan 23, 2020: Cadent Therapeutics announces FDA acceptance of IND application for CAD-1883 for Spinocerebellar Ataxia (SCA)
- Jan 22, 2020: Kissei announces the publication of the results of phase III clinical trials of rovatirelin for the treatment of spinocerebellar degeneration in the Journal of Neurology, Neurosurgery, and Psychiatry
- Dec 04, 2019: Seelos Therapeutics receives notice of allowance for an additional US patent for Trehalose (SLS-005)
- May 29, 2019: Cadent Therapeutics announces FDA Orphan Drug Designation for CAD-1883 for Spinocerebellar Ataxia
- May 07, 2019: Biohaven advances late stage clinical program and novel targets from neuroinnovation platform
- May 03, 2019: Biohaven announces presentation of Troriluzole in phase IIb/III trial at American Academy Of Neurology (AAN) 2019 Annual Meeting
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Anima Biotech Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Annji Pharmaceutical Co Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Biogen Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by BioXcel Corp, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Blade Therapeutics Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Celavie Biosciences LLC, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Corestem Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Dystrogen Therapeutics SA, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Enzerna Biosciences LLC, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Everfront Biotech Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Exicure Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Gene Therapy Research Institution Co Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by IntraBio Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Ionis Pharmaceuticals Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Locanabio Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Novartis AG, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by PTC Therapeutics Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Q-State Biosciences Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Sclnow Biotechnology Co Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Seelos Therapeutics, Inc., 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Shionogi & Co Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Steminent Biotherapeutics Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Triplet Therapeutics Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Vico Therapeutics BV, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Vybion Inc, 2022
- Spinocerebellar Ataxia (SCA) - Pipeline by Wave Life Sciences Ltd, 2022
- Spinocerebellar Ataxia (SCA) - Dormant Projects, 2022
- Spinocerebellar Ataxia (SCA) - Discontinued Products, 2022
- Number of Products under Development for Spinocerebellar Ataxia (SCA), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anima Biotech Inc
- Annji Pharmaceutical Co Ltd
- Biogen Inc
- Biohaven Pharmaceutical Holding Company Ltd
- BioXcel Corp
- Blade Therapeutics Inc
- Celavie Biosciences LLC
- Corestem Inc
- Dystrogen Therapeutics SA
- Enzerna Biosciences LLC
- Everfront Biotech Inc
- Exicure Inc
- Gene Therapy Research Institution Co Ltd
- IntraBio Ltd
- Ionis Pharmaceuticals Inc
- Locanabio Inc
- Novartis AG
- PTC Therapeutics Inc
- Q-State Biosciences Inc
- Sclnow Biotechnology Co Ltd
- Seelos Therapeutics, Inc.
- Shionogi & Co Ltd
- Steminent Biotherapeutics Inc
- Triplet Therapeutics Inc
- Vico Therapeutics BV
- Vybion Inc
- Wave Life Sciences Ltd
